8-K: C4 Therapeutics' Cemsidomide Shows Strong Phase 1 Myeloma Data

C4 Therapeutics announced positive Phase 1 clinical trial data for cemsidomide in relapsed/refractory multiple myeloma, demonstrating a 50% overall response rate at the highest dose and a differentiated safety profile.

Summary

• Cemsidomide, an orally bioavailable IKZF1/3 degrader, demonstrated compelling Phase 1 clinical trial data in combination with dexamethasone for relapsed/refractory multiple myeloma (RRMM).
• The Overall Response Rate (ORR) was 50% at the 100 µg dose level and 40% at the 75 µg dose level in a heavily pre-treated patient population.
• The median duration of response (DOR) was 9.3 months across all dose levels, and not yet reached at the two highest doses (75 µg and 100 µg) as of the July 23, 2025 data cutoff.
• The trial enrolled 72 patients who had received a median of seven prior therapies, with 75% having received prior BCMA-targeted therapy or CAR-T/T-cell engager therapy.
• One patient achieved a minimal residual disease (MRD) negative complete response (CR) at the 100 µg dose level, with another patient converting to CR and one achieving PR after the data cutoff (as of September 5, 2025).
• Cemsidomide in combination with dexamethasone was generally well tolerated, with manageable neutropenia (Grade 3 in 24%, Grade 4 in 33% across all doses) and low rates of febrile neutropenia (4% Grade 3, 1% Grade 4).
• Minimal dose reductions (4 patients; 6%) and no discontinuations related to cemsidomide treatment were observed.
• Pharmacodynamic data showed cemsidomide achieved >50% degradation of IKZF1 and >80% degradation of IKZF3, and led to significant T-cell activation.
• C4 Therapeutics plans to initiate a Phase 2 single-arm registrational trial in Q1 2026 for 4th line or later RRMM and a Phase 1b trial in Q2 2026 for 2nd line or later RRMM in combination with a BCMA BiTE, both pathways having potential for accelerated approval.

Sentiment

Score: 8

Explanation: The filing presents strong positive Phase 1 clinical data for cemsidomide, highlighting its potential as a best-in-class IKZF1/3 degrader with a differentiated safety profile and compelling anti-myeloma activity in a heavily pre-treated patient population. The clear development pathways for accelerated approval and favorable comparison to competitors contribute to a highly positive outlook, despite being early-stage data.

Positives

• Achieved a 50% Overall Response Rate (ORR) at the highest dose level (100 µg) and 40% ORR at the 75 µg dose level in a heavily pre-treated relapsed/refractory multiple myeloma patient population.
• Demonstrated a differentiated safety and tolerability profile with no discontinuations related to cemsidomide and minimal dose reductions (6%).
• Median Duration of Response (DOR) of 9.3 months across all dose levels, with median DOR not yet reached at the two highest doses (75 µg and 100 µg), indicating durable benefit.
• Robust IKZF1/3 degradation and significant T-cell activation were observed, supporting its mechanism of action and potential for combination regimens.
• One patient achieved a minimal residual disease (MRD) negative complete response (CR) at the 100 µg dose level.
• Clear development pathways for two distinct potential accelerated approvals (4th line+ and 2nd line+ in combination with a BCMA BiTE) have been outlined.
• The results position cemsidomide as a potential 'best-in-class' IKZF1/3 degrader, addressing a large and growing unmet need in the multiple myeloma market.

Negatives

• Neutropenia was observed as an on-target effect (Grade 3 in 24% and Grade 4 in 33% across all dose levels), though it was manageable.
• The data presented is from a Phase 1 trial, which is an early stage of clinical development, and further larger-scale trials are required for full regulatory approval.
• Cross-trial comparisons to other IKZF1/3 degraders should be used with caution, as noted in the presentation.

Risks

• Uncertainties related to the initiation, timing, advancement, and conduct of preclinical and clinical studies and other development requirements for product candidates.
• Risk that any one or more product candidates will cost more to develop or may not be successfully developed and commercialized.
• Risk that product candidates will not receive accelerated approval or that the regulatory strategy will need to be redesigned.
• Risk that the results of preclinical studies and/or clinical trials will not be predictive of results in connection with future studies or trials.
• Ability to successfully manufacture and supply product candidates for clinical trials.
• Ability to fund future operations.

Future Outlook

C4 Therapeutics plans to advance cemsidomide through two clinical trials for potential accelerated approvals: a Phase 2 single-arm registrational trial in Q1 2026 for 4th line or later RRMM, with initial ORR data expected in 2H 2027, and a Phase 1b trial in Q2 2026 to evaluate cemsidomide and dexamethasone in combination with a BCMA BiTE for 2nd line or later RRMM, with data expected by mid-2027. The company aims to formally align with the FDA on the recommended Phase 2 dose by the end of 2025.

Management Comments

• "Cemsidomides clinical trial results to date have shown compelling anti-myeloma activity, a differentiated safety and tolerability profile and immunomodulatory effects across all dose levels, which have allowed us to create a derisked development plan that we are prepared to rapidly execute to potentially bring cemsidomide to patients, caregivers and hematologist-oncologists." Len Reyno, M.D., Chief Medical Officer of C4 Therapeutics.
• "As we prepare to initiate the Phase 2 study in Q1 2026 to evaluate cemsidomide in combination with dexamethasone and the Phase 1b study in Q2 2026 to evaluate cemsidomide and dexamethasone in combination with a BCMA BiTE—both development pathways that have the potential for accelerated approval—we are excited to further differentiate cemsidomide as the IKZF1/3 degrader of choice among approved medicines in this class..." Len Reyno, M.D., Chief Medical Officer of C4 Therapeutics.
• "Cemsidomide in combination with dexamethasone is well positioned both as a potential therapeutic option for patients with multi-refractory disease, and as the potential combination regimen of choice with immune-directed therapies due to its ability to enhance the immune response and add additional direct anti-myeloma effects via IKZF1/3 degradation." Binod Dhakal, M.D., M.S., Associate Professor of Medicine, Medical College of Wisconsin.

Industry Context

Multiple myeloma is a rare blood cancer with a large and growing patient population, and despite advances in treatment, it remains incurable with most patients ultimately relapsing. IKZF1/3 degraders are established backbone therapies. Cemsidomide is positioned to address the significant unmet need for new therapeutic options in heavily pretreated patients, including those who have progressed on prior immune-based therapies like BiTEs or CAR-Ts. The company believes cemsidomide's ability to activate T-cells makes it an ideal combination partner for BCMA BiTEs, potentially enhancing efficacy to levels comparable to CAR-Ts while offering a more convenient regimen.

Comparison to Industry Standards

• Cemsidomide's Phase 1 patient population was more heavily pre-treated (median 7 prior therapies, 75% prior BCMA therapy) compared to Mezigdomide (median 6 prior therapies, 12% prior BCMA) and Iberdomide (median 5 prior therapies, N/A prior BCMA) in their respective Phase 1 dose escalation trials.
• Cemsidomide demonstrated minimal treatment disruptive adverse events, with lower rates of Grade >3 infections (6%) and dose reductions due to TEAEs (6%) compared to Mezigdomide (25% infections, 25% dose reductions) and Iberdomide (21% infections, 24% dose reductions).
• Cemsidomide's Overall Response Rate (ORR) at the highest dose level (50% at 100 µg) is comparable to Mezigdomide (55%) and higher than Iberdomide (31%) in their respective Phase 1 dose escalation trials.
• Cemsidomide's median Duration of Response (9.3 months) is comparable to Iberdomide (10.4 months) and higher than Mezigdomide (6.0 months), despite treating a more heavily pre-treated patient population.

Stakeholder Impact

• Shareholders: Positive impact due to promising clinical data, potential for accelerated approval, and large market opportunity, which could increase company valuation.
• Patients: Potential for a new, effective, and well-tolerated treatment option for relapsed/refractory multiple myeloma, especially for heavily pre-treated patients.
• Healthcare Providers: Cemsidomide could become a preferred IKZF1/3 degrader due to its differentiated safety profile and anti-myeloma activity, offering a new tool in their treatment arsenal.

Next Steps

• Formally align with FDA on the recommended Phase 2 dose of cemsidomide by the end of 2025.
• Initiate a Phase 2 single-arm registrational trial in Q1 2026 to evaluate cemsidomide in combination with dexamethasone.
• Initiate a Phase 1b trial in Q2 2026 to evaluate the safety and tolerability of cemsidomide and dexamethasone in combination with a BCMA BiTE.
• Expect initial ORR data from the Phase 2 trial in 2H 2027.
• Expect data from the Phase 1b trial by mid-2027.

Key Dates

Recommendation

The Phase 1 data for cemsidomide in relapsed/refractory multiple myeloma is exceptionally strong, demonstrating a high overall response rate (50% at the highest dose) and a differentiated safety profile with minimal treatment disruptions, especially in a heavily pre-treated patient population. The company has outlined clear and efficient pathways for accelerated approval in significant market segments (2L+ and 4L+), which de-risks future development. Cross-trial comparisons suggest a potentially best-in-class profile compared to other IKZF1/3 degraders. Given the large and growing unmet need in multiple myeloma and the potential for multi-billion dollar peak revenue, these results position C4 Therapeutics for substantial future growth and make the stock a strong buy for long-term investors.

Keywords

C4 Therapeutics, CCCC, Cemsidomide, Multiple Myeloma, RRMM, IKZF1/3 degrader, Phase 1 clinical trial, Dexamethasone, Targeted Protein Degradation, Oncology, Biopharmaceutical, Clinical-stage, BCMA BiTE, FDA accelerated approval